SGLT2 inhibitor results a ‘huge win’ for HFpEF patients

Cardiologists may gain benefits with SGLT2 inhibitors in patients with heart failure with preserved ejection fraction (HFpEF), according to research released at ESC Congress 2021. The EMPEROR-Preserved trial reviewed cardiovascular outcomes in 5988 heart failure patients with >40% ejection fraction who were on empagliflozin or placebo over median 26.2 months. Empagliflozin patients were significantly less ...

Already a member?

Login to keep reading.

© 2021 the limbic